Prognostic significance of WT1 expression in soft tissue sarcoma

Table 2 Correlation between WT1 expression and clinicopathological factors

Clinicopathologic parameters	WT-1 protein expression
	Absent, n = 40 (46.0%)	Present, n = 47 (54.0%)	P value
Age
<50	19 (47.5)	21 (52.5)	0.793
>50	21 (44.7)	26 (55.3)
Histologic type
Liposarcoma	20 (76.9)	6 (23.1)	0.005
MFH	9 (42.9)	12 (57.1)
Leiomyosarcoma	2 (33.3)	4 (66.7)
Rhabdomyosarcoma	1 (8.3)	11 (91.7)
MPNST	2 (28.6)	5 (71.4)
Synovial sarcoma	3 (42.9)	4 (57.1)
Fibrosarcoma	1 (20.0)	4 (80.0)
Others	2 (40.0)	3 (60.0)
Size
<5 cm	3 (23.1)	10 (76.9)	0.072
>5 cm	37 (50.0)	37 (50.0)
Metastasis at Dx
Absent	38 (45.8)	45 (54.2)	0.869
Present	2 (50.0)	2 (50.0)
FNCLCC grade
1	16 (94.1)	1 (5.9)	0.000
2	14 (37.8)	23 (62.2)
3	10 (30.3)	23 (69.7)
Modified grade *
Low	16 (94.1)	1 (5.9)	0.000
High	24 (34.3)	46 (65.7)
AJCC stage
1	15 (83.3)	3 (16.7)	0.003
2	14 (34.1)	27 (65.9)
3	9 (36.0)	16 (64.0)
4	2 (66.7)	1 (33.3)
AJCC modified**
Localized	15 (83.3)	3 (16.7)	0.000
Advanced	25 (36.2)	44 (63.8)

*FNCLCC grade was divided into 2 groups, low grade including FNCLCC group 1 and high grade including FNCLCC grade 2 and 3.
**AJCC stage 1 was defined as localized disease and AJCC stage 2, 3, and 4 were defined as advanced disease.
MFH, Malignant fibrous histiocytoma; MPNST, Malignant peripheral nerve sheath tumor; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; AJCC, American Joint Committee on Cancer.

ISSN: 1477-7819